Company Profile

AdrenoMed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options.

The Company’s lead product candidate is Enibarcimab (INN, former name: Adrecizumab), a clinical-stage, first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat life-threatening conditions associated with increased vascular leakage, congestion and shock. Our current lead indications are sepsis and septic shock.

We translate the concept of precision medicine into acute care. Our biomarker-guided approach enables us to identify the patients with loss of vascular integrity as an underlying pathophysiological disease mechanism and to treat patients that will most likely benefit from Enibarcimab therapy. 

AdrenoMed’s business is effectively secured by a strong IP position with granted patents in all major markets.

AdrenoMed is based in Hennigsdorf near Berlin, Germany.

Executive Management

Dr. Richard Jones

Chief Executive Officer (CEO)

Dr. Richard Jones, Chief Executive Officer (CEO) of AdrenoMed, provides over 25 years of experience in the pharmaceutical and biotech industry with a strong record of achievements in business, clinical development and commercialization. Before joining AdrenoMed in March 2022, Dr. Jones served as CEO of Fusion Antibodies Plc. Previously, he was CEO for several UK and European private companies as well as SVP, Head of Europe for a US based public company. Also, he gained expertise at Novartis and GSK as VP, Medicines Commercialization Leader, Global Haematology at both companies.

David Germonpré, MSc/Executive MBA

Chief Financial Officer (CFO)

David Germonpré, Chief Financial Officer (CFO), has over 15 years of experience as finance leader and strategist. Before joining AdrenoMed in July 2022, Mr. Germonpré was Partner at MTIP, a Switzerland-based health-tech growth capital investor. Previously, for the Gemma Frisius Fund he invested in spinouts from Belgium’s KU Leuven. Between 2009 and 2013 David advised the Government of Flanders on its VC and PE programs. Prior to that he worked as investment banker at Dexia Bank, executing M&As and IPOs of big corporates.

Dr. Stephan Witte

Chief Medical Officer (CMO)

Dr. Stephan Witte is a drug development professional with over 20 years’ experience in clinical drug development and registration and a strong disease expertise in sepsis and septic shock. Before joining AdrenoMed, Stephan Witte, Ph.D., was Vice President Clinical Science & Operations at Atriva Therapeutics, a clinical-stage biotech company focusing on antiviral therapeutics. Prior to that, he was Vice President Clinical Trials at Breath Therapeutics and Head of Clinical Development and Regulatory Affairs at Inotrem, a biotech company specializing in inflammatory syndromes including septic shock.

Supervisory Board

Dr. Erich Schlick (Chairman)

Independent management consultant with over 40 years of experience in the pharma industry

Dr. Priyanka Belawat

Investment Advisor at HBM Partners

Dr. Renke Lührs

Partner at Buse Heberer Fromm

Dr. Metod Miklus

CEO of ExpoCapital GmbH and co-founder of B·R·A·H·M·S AG

Dr. Gerald Moeller

Independent management consultant, co-founder and former CEO of AdrenoMed

Dr. Christoph Springer

Independent Advisor

Dr. Rainer Strohmenger

Managing Partner at Wellington Partners



AdrenoMed is dedicated to saving the lives of critically ill patients by translating the concept of personalized medicine to acute care. We are targeting Adrenomedullin, a peptide hormone with protective effects on endothelial barrier integrity. With a biomarker guided approach utilizing the target Adrenomedullin for patient selection, AdrenoMed is developing a unique and holistic approach to rescue vascular integrity in life-threatening conditions such as sepsis and septic shock.


The Company’s lead product candidate is Enibarcimab (HAM8101; fomer name: Adrecizumab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity

Enibarcimab mode of action

Enibarcimab targets Adrenomedullin (ADM), a vasoprotective peptide hormone. As a small peptide, ADM can easily leave the bloodstream by crossing the endothelial barrier and entering the extravascular space, where it affects vascular smooth muscle cells (VSMC) and regulates vascular tone by promoting vasodilation—an unwelcome effect in the context of sepsis as it contributes to increased hypotension and organ damage. ADM that remains in the bloodstream, however, has a different effect, one that helps mitigate sepsis: promoting stability of the endothelial barrier by restoring the cell junctions between endothelial cells that ordinarily regulate molecule transport and leakage. In health, levels of ADM in the bloodstream and extravascular space are in equilibrium so that endothelial barrier integrity is maintained and blood pressure remains normal.

Loss of vascular integrity in septic shock

Enibarcimab therapeutic approach

In sepsis, more ADM is produced to counteract loss of endothelial barrier function, but as the endothelial barrier becomes more permeable as a result of systemic immune dysregulation, more ADM enters the extravascular space in a dangerous cycle that can contribute to shock and organ failure.

Administration of the monoclonal antibody Enibarcimab results in an elevation of ADM concentration within the circulation. The ADM-Enibarcimab complex is functional, thus ADM can still act on the endothelium. Consequently, Enibarcimab treatment immediately and precisely promotes ADM’s protective effects on the endothelial barrier.

For further information on the mode of action of Enibarcimab see title story and editorial in the peer-reviewed journal SHOCK (Shock, 2018).

Suitability of using Enibarcimab to treat loss of vascular integrity is based on evidence obtained in multiple preclinical intensive care-like vascular integrity models with Enibarcimab applied on top of mimicked human standard of care treatment (e.g. fluids, vasopressors).

Enibarcimab treatment significantly improves all clinically relevant endpoints such as reduction of vascular leakage and vasopressor demand, stabilization of the circulation, normalization of fluid balance and kidney function. In preclinical septic shock models, Enibarcimab reduced the mortality by 50% (Intens Care Med Exp, 2013; Intens Care Med, 2013; Shock, 2018).

Furthermore, based on analyses of blood samples from well-defined patients, Adrenomedullin was reported as a therapeutic target and biomarker (bio-ADM®) for vascular integrity in several peer-reviewed scientific articles (Crit Care Med,  2020; Crit Care, 2018; Shock, 2018).
The recently marketed Adrenomedullin assay (sphingotest® bio-ADM®) allows the identification of patients suffering from loss of vascular integrity and will enable physicians to specifically treat these people by using Enibarcimab.

clinical development

The lead candidate Enibarcimab is ready for a pivotal trial. In the AdrenOSS-2 (proof-of-concept phase II trial in septic shock) Enibarcimab demonstrated a favorable safety profile, was well tolerated and showed improved organ function and survival compared to placebo.

The monoclonal antibody Enibarcimab, presented a favorable safety profile in septic shock patients. Thereby meeting the primary trial objective. An improvement of organ function and a subsequent reduction of mortality has been observed.

A pre-specified biomarker analysis illustrated that treatment with Enibarcimab after ICU admission resulted in a rapid and sustained improvement of systemic organ function (SOFA score). Subsequently, the relative mortality was reduced by more than 30% after day 28. The positive effect on survival persisted over 90 days.

For further information please see the following article.

The biomarker-guided, randomized, double-blind, placebo-controlled proof-of-concept trial AdrenOSS-2 investigated the safety, tolerability and efficacy of Enibarcimab in 301 patients with early septic shock and elevated blood levels of Adrenomedullin. The multi-centre trial was carried out in Belgium, France, Germany and the Netherlands. In addition to standard of care, patients received Enibarcimab or placebo. The Phase II trial design was published in BMJ Open (BMJ Open, 2019).

Results of Phase I trials evaluating Enibarcimab safety and tolerability

The randomized, double-blind, placebo-controlled Phase Ia and Ib studies included a total of forty-eight healthy volunteers to evaluate escalating doses of Enibarcimab.

Enibarcimab demonstrated an excellent safety profile in both studies. Additionally, the Phase Ib study in systemic inflammation indicated dose-dependent beneficial effects of Enibarcimab on vascular integrity without affecting inflammatory parameters. Results of the Phase Ia/b trials were published in the British Journal of Clinical Pharmacology (Br J Clin Pharmacol, 2018).


Vascular integrity – fundamental for human health

Regulation of vascular integrity is a fundamental process for human physiology and pathology. The vascular endothelium is the essential organ for the function of blood vessels in the human body. It is a cell monolayer that forms an essential and selective barrier between the blood vessels and the tissue compartment. The vascular endothelium actively maintains more than 100,000 kilometers of blood vessels.

Conditions that are most threatening to life, such as sepsis, septic shock, and acute heart failure, are driven by severe impairment of the vascular endothelial barrier presenting in porous, leaky blood vessels and resulting in tissue congestion and edema. Ultimately, the rapid fall in blood pressure and diminished oxygen supply to organs leads to multiple organ failure and death.

Adrenomedullin (ADM) – key regulator of vascular integrity

Since its discovery in 1993, the vasoprotective hormone Adrenomedullin has attracted a great deal of interest as a multifunctional regulator of the vascular system.
In the circulation, Adrenomedullin directly tightens the gaps between endothelial cells, subsequently preventing vascular leakage.

Adrenomedullin (bio-ADM®) was validated as therapeutic target and biomarker as reported in several scientific publications. Rising bio-ADM® values in patients’ blood samples clearly indicate a worsening of vascular integrity independent from inflammation or any other comorbidity, reflecting the patients need for a targeted therapy addressing this pathophysiology.

Sepsis & Septic Shock

Every year, millions of people around the world are affected by sepsis. In the US, sepsis contributes to between one third and half of deaths of hospitalized people, making it the number one cause of death in hospitals (JAMA, 2014). The annual cost of treating sepsis patients amounts to US$24 billion (Crit Care Med, 2018) in the US alone.

Sepsis has been defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (JAMA, 2016). This means that the body’s systemic immune reaction to an infecting pathogen gets out of control and starts affecting tissues and organs. Alongside these inflammatory responses, different regulatory systems such as cardio-vascular, metabolic and coagulation are affected.

A central driver of the pathogenesis of sepsis is the increasing loss of endothelial barrier function. In other words: The loss of vascular integrity. This leads to an uncontrolled leakage of fluid, proteins and cells into the surrounding tissue.

Patients suffer from a rapid drop in blood pressure (hypotension) and strong abnormalities in circulatory, cellular, and metabolic function. The reduced blood pressure, which further limits oxygen supply to organs (hypoperfusion), contributes to the development of multi-organ failure and death.

The current standard of care for septic shock patients is limited to anti-infectives, administration of vasopressors, fluids and supportive care.

With a biomarker-guided approach utilizing Adrenomedullin as a diagnostic marker and therapeutic target, Enibarcimab addresses the loss of vascular integrity to reduce vascular leakage, restore hemodynamic stability and consequently improve organ function and reduce mortality.

Press Releases

media coverage



AdrenoMed– a clinical-stage biopharmaceutical company, located in the Berlin area.

We are a multi-disciplinary, international team committed to pioneering the development of precision medicine for critically ill patients with limited treatment options.

We are always looking for talented, dedicated professionals to join our team. Please submit a resume and cover letter to career@adrenomed.com.

Please see our applicant and candidate privacy policy.